Imipenem Drug Combination Cilastatin (Primaxin)

Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent.

Also Known As:

Primaxin; Cilastatin, Imipenem Drug Combination; Imipenem - Cilastatin; Imipenem - Cilastatin Sodium; Imipenem Cilastatin; Imipenem Cilastatin Sodium; Imipenem-Cilastatin; Imipenem-Cilastatin Sodium; Imipenem-Cilastatin, Sodium Salt; MK 0787-MK 0791 mixture; MK 787-MK 791 mixture; Thienam; Tienam 500; Zienam; Cilastatin, Imipenem; Imipenem Cilastatin, Sodium Salt; MK 0787 MK 0791 mixture; MK 787 MK 791 mixture

Networked: 736 relevant articles (119 outcomes, 192 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Okuno, Yuji: 7 articles (06/2022 - 06/2013)
2.	Paschke, Amanda: 6 articles (12/2021 - 10/2016)
3.	Rizk, Matthew L: 5 articles (01/2022 - 10/2016)
4.	Young, Katherine: 5 articles (01/2022 - 01/2018)
5.	Brown, Michelle L: 5 articles (12/2021 - 10/2016)
6.	Butterton, Joan R: 5 articles (12/2021 - 01/2018)
7.	Kohno, Shigeru: 5 articles (02/2021 - 01/2002)
8.	Shibuya, Masahiko: 4 articles (06/2022 - 01/2021)
9.	Du, Jiejun: 4 articles (12/2021 - 01/2017)
10.	Kuti, Joseph L: 4 articles (02/2008 - 01/2005)

Related Diseases

1.	Infections 02/01/1988 - "Imipenem/cilastatin is highly effective for infections in many body sites against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. " 12/01/1986 - "In this study imipenem/cilastatin was used successfully to treat 21 patients with a variety of severe infections caused by Gram-positive and Gram-negative aerobic bacteria. " 01/01/1991 - "The efficacy and low incidence of side effects of the intramuscular formulation of imipenem/cilastatin are significant advantages in the cost-effective treatment of infections." 01/01/1987 - "Clinical trials have shown that imipenem/cilastatin given intravenously is effective in the treatment of mild, moderate or severe infections. " 01/01/1996 - "Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections."
2.	Intraabdominal Infections 09/01/2000 - "It also offers improved CNS tolerability compared with imipenem/cilastatin with the option of a higher maximum dosage, which may be a particular advantage in patients with severe intra-abdominal infections." 06/01/1992 - "Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections." 06/01/1987 - "Treatment of intra-abdominal infections using imipenem/cilastatin." 07/01/1985 - "The clinical and microbiologic results for 164 assessable patients given imipenem/cilastatin for intraabdominal infections are reported. " 07/01/1985 - "Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience."
3.	Urinary Tract Infections (Urinary Tract Infection) 03/01/1992 - "[Clinical studies of efficacy of imipenem/cilastatin sodium against urinary tract infections with ureterocutaneostomy]." 06/07/1985 - "Safety and efficacy of imipenem/cilastatin in treatment of complicated urinary tract infections." 12/01/2015 - "Another phase II clinical trial has demonstrated that clinical cure rates with CAZ/AVI are comparable to those with imipenem/cilastatin for the treatment of adults with complicated urinary tract infections (cUTIs). " 07/01/1997 - "[Efficacy and safety of intramuscular imipenem/cilastatin (IPM/CS) for complicated urinary tract infections]." 01/01/1992 - "To determine the cost relative to efficacy and tolerability of two antimicrobial regimens, a prospective, multicenter study compared imipenem-cilastatin (I-C) monotherapy with clindamycin+aminoglycoside (C+A) in the treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections. "
4.	Pneumonia (Pneumonitis) 02/01/1985 - "Results of this study suggest that primaxin will be useful in the treatment of a variety of serious Gram-positive and Gram-negative pneumonias. " 12/01/2004 - "One week later, the patient developed pneumonia, and imipenem/cilastatin was added. " 04/01/2003 - "Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia." 11/01/1994 - "[A case of severe pneumonia in an elderly man, caused by Citrobacter freundii suspected to have a low susceptibility to imipenem/cilastatin sodium]." 06/26/1985 - "This pilot study assessed the efficacy, safety and tolerance of intravenously administered imipenem/cilastatin in the treatment of adults hospitalised with community acquired pneumonia. "
5.	Peritonitis 09/01/2004 - "We studied the efficacy of imipenem/cilastatin monotherapy in the treatment of PD-related peritonitis. " 06/01/1992 - "[Study of the efficacy and tolerance of imipenem-cilastatin used as monotherapy for the adjuvant treatment to surgery of peritonitis. " 06/01/1990 - "[Study of the intraperitoneal penetration of imipenem/cilastatin in acute peritonitis with perforation]." 09/01/2017 - "Concerns Regarding ISPD Recommendations for Peritonitis in Relation to Imipenem/Cilastatin-In Reply." 10/01/1998 - "Altogether 154 patients (77 Imipenem/Cilastatin group, 77 alternative group) that displayed Mannheim Peritonitis Scores between 16 and 26 (average 20.8) were analyzed. "

Related Drugs and Biologics

1.	Meropenem (Merrem)
2.	Anti-Bacterial Agents (Antibiotics)
3.	Clindamycin (Cleocin)
4.	Ceftazidime (Fortum)
5.	Vancomycin
6.	Aminoglycosides
7.	Imipenem
8.	Tazobactam Drug Combination Piperacillin (Zosyn)
9.	Ciprofloxacin (Cipro)
10.	Tigecycline (Tygacil)

Related Therapies and Procedures

1.	Therapeutics
2.	Microspheres (Microsphere)
3.	Drug Therapy (Chemotherapy)
4.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
5.	Continuous Renal Replacement Therapy